GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Rumour Verification - Regulation 30(11)
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Exchanges (NSE and BSE) asked GlaxoSmithKline Pharmaceuticals India to clarify a Moneycontrol article titled 'Trump Tariff News Live: GSK and AstraZeneca among top companies told to cut US prices or else'. The company clarified that the news item pertains to its UK ultimate parent, GSK plc, and NOT to the Indian listed entity. GlaxoSmithKline Pharmaceuticals India stated it has no additional information on the matter and does not see any bearing on its share price. No undisclosed price-sensitive information exists in the company's view.
Neutral to slightly positive for the Indian stock, as the company is distancing itself from negative news affecting its UK parent. Retail investors should note that this is a routine clarification confirming the Indian listed company is not directly impacted by the Trump tariff-related US pricing pressure story.